# 2025年12月20日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 红细胞输注与不良临床结局之间的关联独立于心脏病史：多中心观察性 InPUT 研究分析。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413913)
**期刊：** Critical care (London, England)
**PMID：** 41413913
**DOI：** 10.1186/s13054-025-05745-5

### 第一部分 原文与翻译

**英文原标题：** Association between red blood cell transfusion and adverse clinical outcomes is Independent of cardiac history: a multicenter observational InPUT study analysis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

该研究利用多中心观察性 InPUT 数据，探讨红细胞输注与不良临床结局之间的关系，并评估该关系是否受患者既往心脏病史影响。结果显示，即使考虑心脏病史，红细胞输注仍与不良结局独立相关，提示输血管理需更为谨慎。研究在临床风险分层及输血决策优化方面具有潜在参考价值，但由于缺乏随机对照设计，因果推断仍需进一步验证。

---

## 2. 白介素-27在母胎界面对寨卡病毒具有抗病毒作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413389)
**期刊：** Nature communications
**PMID：** 41413389
**DOI：** 10.1038/s41467-025-67378-0

### 第一部分 原文与翻译

**英文原标题：** Interleukin-27 is antiviral against Zika virus at the maternal-fetal interface.

> **英文摘要：**
> Congenital viral infections can have severe consequences for pregnancy and fetal outcomes. Remarkably, the fetal-derived placenta serves as a robust barrier to infection through meticulous regulation by immune effectors and cytokines. Yet, the regulatory roles of many cytokines remain undefined at the maternal-fetal interface, including Interleukin-27 (IL-27). Here, we show that trophoblast organoids derived from human placentas constitutively express both IL-27 and its receptor, and restrict Zika virus infection through IL-27 signaling. Through bulk RNA-sequencing of trophoblast organoids in the absence and presence of IL-27 signaling, we demonstrate IL-27-mediated upregulation of antiviral genes. Finally, we show that IL-27 signaling is critical to restricting placental viral burdens and protecting against pathologic fetal outcomes during murine congenital Zika virus infection. In this work, we demonstrate a novel role for IL-27 in the placenta and establish IL-27 as an innate antiviral defense at the maternal-fetal interface during congenital viral infection.

> **中文摘要：**
> 先天性病毒感染可能对妊娠和胎儿结局造成严重影响。值得注意的是，由胎儿来源的胎盘通过免疫效应因子和细胞因子的精细调控，充当了抵抗感染的强大屏障。然而，在母胎界面上，许多细胞因子的调控作用仍未明了，包括白介素-27（IL-27）。本研究显示，人胎盘来源的滋养层类器官持续表达IL-27及其受体，并通过IL-27信号限制寨卡病毒感染。通过对存在与缺失IL-27信号条件下的滋养层类器官进行整体RNA测序，我们证明IL-27可介导抗病毒基因的上调。最后，我们表明，在小鼠先天性寨卡病毒感染模型中，IL-27信号对于限制胎盘病毒负荷并防止病理性胎儿结局至关重要。本研究揭示了IL-27在胎盘中的新作用，并确立了其作为母胎界面先天抗病毒防御因子的地位。

### 第二部分 AI 大师评价

该研究旨在阐明白介素-27（IL-27）在母胎界面抗病毒防御中的作用。通过人源滋养层类器官模型和整体RNA测序，作者证实IL-27不仅在正常条件下持续表达，还能上调抗病毒相关基因，从而限制寨卡病毒感染。动物实验进一步验证IL-27信号可降低胎盘病毒负荷并改善胎儿结局。研究创新性地揭示了IL-27作为母胎界面先天免疫屏障的新功能，为防治先天性病毒感染提供了新的免疫学思路，但仍需在人体内进一步验证其机制和临床相关性。

---

## 3. β-肾上腺素能信号通过促进病毒清除和气道保护来调控新生期呼吸道合胞病毒感染

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413286)
**期刊：** Nature communications
**PMID：** 41413286
**DOI：** 10.1038/s41467-025-66401-8

### 第一部分 原文与翻译

**英文原标题：** β-adrenergic signaling controls neonatal respiratory syncytial virus infection by promoting viral clearance and airway protection.

> **英文摘要：**
> Respiratory syncytial virus (RSV) is the most common cause of acute bronchiolitis and pneumonia in children under 5 years of age. RSV infection is characterized by lung inflammation, viral expansion, and airway barrier destruction. The crosstalk between neurons and immune and non-immune cells develops from early life onwards. The lungs and airways are densely innervated by sympathetic neurons where they secrete the neurotransmitter noradrenaline (NA) at homeostasis and following injury in adult mice. NA, once secreted into the lungs, can act on immune and non-immune cells through β-adrenergic receptors (β-ARs). However, it is unknown whether NA-β-AR signaling axis regulates antiviral immunity during early-life infections. In a mouse model of neonatal RSV infection, we find that stimulation of adrenergic signaling via β-AR agonist increases viral clearance, anti-inflammatory responses, and disease recovery. By contrast, loss of sympathetic neurons and β-AR increases the RSV viral load and immunopathology in neonates. Stimulating β-AR signaling has several downstream effects, including reduced airway mucus secretion and protection from endothelial barrier disruption, which together prevent airway blockade, respiratory failure, and facilitate control of RSV infection. Collectively, our studies demonstrate that sympathetic neurons and β-AR signaling protect neonates from viral expansion and lung barrier breakdown, promoting antiviral defense.

> **中文摘要：**
> 呼吸道合胞病毒（RSV）是5岁以下儿童急性细支气管炎和肺炎的最常见病因。RSV感染的特征包括肺部炎症、病毒扩增以及气道屏障破坏。神经元与免疫细胞和非免疫细胞之间的相互作用从生命早期即开始形成。肺和气道由交感神经元密集支配，这些神经元在稳态及成年小鼠受损后分泌神经递质去甲肾上腺素（NA）。一旦NA分泌至肺内，即可通过β-肾上腺素能受体（β-AR）作用于免疫及非免疫细胞。然而，尚不清楚NA–β-AR信号轴是否在早期生命感染期间调控抗病毒免疫。在新生鼠RSV感染模型中，我们发现通过β-AR激动剂刺激肾上腺素能信号可增强病毒清除、抗炎反应及疾病恢复。相反，交感神经元和β-AR的缺失会导致新生鼠RSV病毒载量升高及免疫病理加重。β-AR信号的激活具有多种下游效应，包括减少气道黏液分泌及防止内皮屏障受损，这些作用共同防止气道阻塞、呼吸衰竭并有助于控制RSV感染。总体而言，本研究表明交感神经元及β-AR信号可保护新生个体免受病毒扩增和肺屏障崩解的影响，促进抗病毒防御。

### 第二部分 AI 大师评价

本研究聚焦于交感神经和β-肾上腺素能信号在新生期呼吸道合胞病毒感染中的免疫调控作用。研究者利用新生鼠模型，揭示激活β-AR信号可促进病毒清除、缓解炎症反应并保护肺气道屏障。与此相反，交感神经或β-AR缺失会加重病毒负荷和病理损伤。这项研究创新性地揭示了神经–免疫互作在早期生命抗病毒防御中的关键作用，为治疗新生儿RSV感染提供了潜在的新靶点，但机制的临床可转化性仍需进一步验证。

---

## 4. 干预时机与疾病阶段决定了特考韦瑞和西多福韦在雄性 SCID 小鼠中的疗效表现

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41413043)
**期刊：** Nature communications
**PMID：** 41413043
**DOI：** 10.1038/s41467-025-67548-0

### 第一部分 原文与翻译

**英文原标题：** Intervention timing and disease stage shape tecovirimat and cidofovir efficacy in male SCID mice.

> **英文摘要：**
> Currently, mpox virus (MPXV) continues to pose a global public health challenge, with immunocompromised individuals often exhibiting more severe clinical symptoms. This study screens three male mouse models (ICR, IFNAR1, SCID) and identifies SCID mice as the optimal model for modeling severe patient symptoms, including pneumonia, rash, and localized inflammation, which is applied to evaluate the antiviral efficacy of tecovirimat and cidofovir. Both drugs prevent systemic MPXV spread when administered within two days post virus exposure. Local antiviral efficacy differs between the two drugs, particularly after intradermal infection. Prolonged treatment up to 28 days post infection results in 100% survival of SCID mice but fails to effectively suppress localized rash and inflammatory swelling, suggesting that the drugs have limited impact at later stages of the disease. These findings indicate that the therapeutic efficacy of tecovirimat and cidofovir depends on the timing of intervention initiation and the stage of disease progression.

> **中文摘要：**
> 目前，猴痘病毒（MPXV）仍然对全球公共卫生构成重大挑战，免疫功能受损个体常表现出更为严重的临床症状。本研究筛选了三种雄性小鼠模型（ICR、IFNAR1、SCID），并确定 SCID 小鼠是模拟重症患者症状（包括肺炎、皮疹及局部炎症）的最佳模型，用于评估特考韦瑞（tecovirimat）和西多福韦（cidofovir）的抗病毒疗效。两种药物在病毒暴露后两天内给药均可阻止 MPXV 的系统性扩散。局部抗病毒疗效在两种药物之间存在差异，特别是在皮内感染后。将治疗持续至感染后 28 天可实现 SCID 小鼠的 100% 生存率，但无法有效抑制局部皮疹及炎性肿胀，提示药物在疾病后期的效果有限。这些结果表明，特考韦瑞和西多福韦的治疗效果取决于干预启动的时机及疾病进展阶段。

### 第二部分 AI 大师评价

该研究旨在探索特考韦瑞与西多福韦在不同干预时机及疾病阶段的疗效差异。通过比较三种小鼠模型，研究明确了 SCID 小鼠适用于重症猴痘的模拟，为药物疗效评估提供了理想平台。结果揭示早期干预可显著防止病毒扩散，而延迟治疗虽可提高生存率但难以控制局部炎症，强调了治疗时机的关键性。该研究的创新在于结合模型选择与干预时序的系统性实验设计，但局限在于动物模型与人类临床反应之间仍存在差距。

---

## 5. FEVQ 作为尼泊尔、秘鲁和乌干达肺功能的无种族偏倚评估方法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41412721)
**期刊：** The European respiratory journal
**PMID：** 41412721
**DOI：** 10.1183/13993003.01830-2025

### 第一部分 原文与翻译

**英文原标题：** FEVQ as a race-neutral assessment of lung function in Nepal, Peru and Uganda.

> **英文摘要：**
> BACKGROUND: FEVQ (Forced Expiratory Volume in 1 s Quotient) is a race-neutral expression of lung function. The validity and utility of FEVQ across Global South populations has not been previously explored.
> 
> METHODS: We conducted a post-hoc analysis of data from the Global Excellence in COPD Outcomes-1 (GECo1 and GECo2) studies in which a random age- and sex-stratified population of 10 709 people were recruited in Nepal, Peru and Uganda. The FEV first percentile (used to derive FEVQ) was estimated in those with COPD by site and sex. We examined associations between FEVQ, risk factors and respiratory morbidity. We estimated the rate of decline in FEVQ. We evaluated the discriminative accuracy of FEVQ in diagnosing COPD.
> 
> FINDINGS: The first percentile FEV in those with COPD at 0·43 L in women and 0·52 L in men is similar to those previously used to calculate FEVQ. Lower FEVQ was associated with older age, lower socioeconomic status, shorter height, and greater smoking pack-years. We estimated that decline in FEVQ with age was 0·65 (95%CI: 0·64; 0·67) units/10 years, more rapid in those continuing to smoke at 0·82 (95%CI: 0·77; 0·87) units/10 years. FEVQ was lower in those with prior respiratory hospitalizations and impairment in daily activities due to respiratory disease, and associated with future hospitalization risk in the GECo2 study. Pre-bronchodilator FEVQ had reasonable diagnostic accuracy for COPD (AUC 0·87(95%CI:0·85-0·88)), similar to pre-bronchodilator FEV% predicted (AUC 0·88(95%CI:0·87-0·90)).
> 
> INTERPRETATION: Our data support the validity and utility of FEVQ as a race-neutral approach to lung function assessment in diverse settings, including the Global South where the burden of lung disease is greatest.
> 
> FUNDING: This study was funded by the Medical Research Council (grant MR/P008984/1) under a Global Alliance for Chronic Diseases call. JRH is funded by the NIHR (project reference 303125) using UK international development funding from the UK Government to support global health research. The views expressed in this publication are those of the authors and not necessarily those of the NIHR or the UK government.

> **中文摘要：**
> 背景：FEVQ（第一秒用力呼气量商数）是一种无种族偏倚的肺功能表达方式。此前尚未探索 FEVQ 在全球南方人群中的有效性和实用性。
> 
> 方法：我们对全球慢阻肺结局卓越（GECo1 和 GECo2）研究的数据进行了事后分析，该研究在尼泊尔、秘鲁和乌干达随机招募了按年龄和性别分层的 10,709 名受试者。我们在慢阻肺患者中按研究地点和性别估计了第一百分位数的 FEV（用于推导 FEVQ）。我们分析了 FEVQ 与危险因素及呼吸系统发病率之间的关联，并估计了 FEVQ 的下降速率。我们还评估了 FEVQ 在诊断慢阻肺方面的区分准确性。
> 
> 结果：慢阻肺患者的第一百分位数 FEV 为女性 0.43 L、男性 0.52 L，与既往用于计算 FEVQ 的数值相似。较低的 FEVQ 与年龄较大、社会经济地位较低、身高较矮以及吸烟史（包年数）较多相关。我们估计 FEVQ 随年龄下降 0.65 个单位/10 年（95%CI：0.64；0.67），持续吸烟者下降更快，为 0.82 个单位/10 年（95%CI：0.77；0.87）。既往有呼吸系统住院史或因呼吸疾病影响日常活动者的 FEVQ 水平较低，在 GECo2 研究中也与未来住院风险相关。支气管扩张剂前的 FEVQ 对慢阻肺诊断具有良好的准确性（AUC 0.87，95%CI：0.85-0.88），与支气管扩张剂前预测 FEV% 类似（AUC 0.88，95%CI：0.87-0.90）。
> 
> 结论：我们的数据支持 FEVQ 作为一种无种族偏倚的肺功能评估方法，在包括肺部疾病负担最重的全球南方国家等多样化环境中具有有效性和实用性。
> 
> 基金支持：本研究由英国医学研究委员会（项目编号 MR/P008984/1）通过慢性病全球联盟资助。JRH 获英国国家卫生研究院（项目编号 303125）资助，资金来源为英国政府国际发展资金以支持全球健康研究。本文所表达的观点仅代表作者本人，不必然反映 NIHR 或英国政府的立场。

### 第二部分 AI 大师评价

该研究旨在验证 FEVQ 作为一种无种族偏倚的肺功能评估指标在尼泊尔、秘鲁和乌干达等全球南方人群中的可行性。通过对 GECo1 与 GECo2 数据进行事后分析，研究发现 FEVQ 的变化规律与年龄、吸烟史及社会经济因素密切相关，并能较好区分慢阻肺患者。结果表明 FEVQ 在不同种族和地区均具有诊断一致性和实用价值，体现了在全球背景下推进公平肺功能评估的重要意义。其局限性主要在于研究为事后分析，外推性仍需进一步验证。

---

## 6. 成纤维细胞活化蛋白作为慢性肺移植异体功能障碍早期生物标志物的探索

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41412718)
**期刊：** The European respiratory journal
**PMID：** 41412718
**DOI：** 10.1183/13993003.01738-2025

### 第一部分 原文与翻译

**英文原标题：** Exploring fibroblast activation protein as an early biomarker in chronic lung allograft dysfunction.

> **英文摘要：**
> QUESTION: Chronic lung allograft dysfunction (CLAD) is the leading cause of late graft failure after lung transplantation. Fibroblast activation protein (FAP) is selectively upregulated in activated fibroblasts under fibrotic conditions. We asked whether FAP expression is increased in chronic lung allograft dysfunction and whether it can serve as an early diagnostic marker.
> 
> MATERIALS AND METHODS: We performed single-cell RNA sequencing on two murine orthotopic lung transplant models (C57BL/6→C57BL/10 and BALB/c→C57BL/6) and human lung tissue from five controls and five patients with CLAD. We quantified FAP expression by immunohistochemistry in transbronchial biopsies from 240 lung transplant recipients (62 with CLAD and 178 without CLAD). Receiver-operating characteristic curves determined an optimal FAP-positive area threshold. Kaplan-Meier analysis and Cox proportional hazards models assessed the association between FAP positivity and CLAD.
> 
> RESULTS: In both murine and human single-cell data, FAP expression was confined to pathogenic fibroblast subsets and was significantly elevated in CLAD. In the clinical cohort, a threshold of 10.8 percent FAP-positive area discriminated chronic dysfunction with an area under the curve of 0.78 (95% CI, 0.72-0.85), sensitivity of 65%, and specificity of 84%. FAP positivity predicted shorter CLAD-free survival (p<0.0001) and overall survival (p=0.03). The hazard ratio for CLAD was 5.23 (95% CI, 3.11-8.82; p<0.001), remaining significant after multivariable adjustment (hazard ratio 5.43; 95% CI, 3.22-9.16; p<0.001).
> 
> ANSWER: FAP expression is elevated in CLAD and is associated with subsequent CLAD and survival. Tissue FAP may enable early risk stratification and inform clinical surveillance; however, given its moderate discrimination, prospective validation in multicenter cohorts is warranted.

> **中文摘要：**
> 问题：慢性肺移植异体功能障碍（CLAD）是肺移植后晚期移植物衰竭的主要原因。成纤维细胞活化蛋白（FAP）在纤维化条件下的活化成纤维细胞中选择性上调。我们探讨FAP在CLAD中是否表达增加，以及其能否作为早期诊断标志物。
> 
> 材料与方法：我们对两个小鼠原位肺移植模型（C57BL/6→C57BL/10 和 BALB/c→C57BL/6）以及来自5例对照者和5例CLAD患者的人肺组织进行了单细胞RNA测序。通过免疫组化对240例肺移植受者（其中62例为CLAD，178例为非CLAD）的支气管镜下活检样本进行FAP表达定量。采用受试者工作特征曲线确定FAP阳性面积的最佳阈值。采用Kaplan-Meier分析和Cox比例风险模型评估FAP阳性与CLAD之间的关联。
> 
> 结果：在小鼠和人类的单细胞数据中，FAP表达局限于致病性成纤维细胞亚群，并在CLAD中显著升高。在临床队列中，10.8%的FAP阳性面积阈值可区分慢性功能障碍，其曲线下面积为0.78（95% CI，0.72-0.85），敏感性为65%，特异性为84%。FAP阳性可预测较短的无CLAD生存期（p<0.0001）及总体生存期（p=0.03）。CLAD的风险比为5.23（95% CI，3.11-8.82；p<0.001），在多变量调整后仍具有统计学显著性（风险比5.43；95% CI，3.22-9.16；p<0.001）。
> 
> 结论：FAP表达在CLAD中升高，并与随后的CLAD发生及生存相关。组织FAP可能有助于早期风险分层和临床监测；然而，鉴于其中度的鉴别力，仍需在多中心队列中进行前瞻性验证。

### 第二部分 AI 大师评价

本研究旨在探讨成纤维细胞活化蛋白（FAP）在慢性肺移植异体功能障碍中的表达及其作为早期生物标志物的潜力。研究结合小鼠模型与人肺组织的单细胞转录组数据，并通过大样本临床活检进行免疫组化验证。结果显示FAP在CLAD中的上调具有显著预测价值，且与患者的生存时间密切相关。该研究在移植后病理机制与早期诊断领域具有创新性，但仍需进一步多中心前瞻性验证以确认其临床应用价值。

---

## 7. 房地产投资信托（REIT）收购后医院财务绩效与护理质量的变化：一项准实验性差异中的差异研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41412593)
**期刊：** BMJ (Clinical research ed.)
**PMID：** 41412593
**DOI：** 10.1136/bmj-2025-086226

### 第一部分 原文与翻译

**英文原标题：** Changes in hospital financial performance and quality of care after real estate investment trust acquisition: quasi-experimental difference-in-differences study.

> **英文摘要：**
> OBJECTIVE: To evaluate changes in hospital financial performance and patient quality of care after real estate is leased back to a real estate investment trust (REIT) acquired hospital.
> 
> DESIGN: Quasi-experimental difference-in-differences study.
> 
> SETTING: Hospital Medicare cost reports, 100% Medicare hospital claims from 2002 to 2021.
> 
> PARTICIPANTS: 87 REIT acquired hospitals and 337 non-REIT acquired matched controls.
> 
> MAIN OUTCOME MEASURES: Changes in hospital financial performance (fixed assets, fixed assets (buildings), net patient revenue, operating expenses, full time equivalent (FTE) nurses, employees on payroll (FTE), net income, total margin, operating margin, current ratio (current assets/current liabilities), days cash on hand, bankruptcy, and closure) and quality of care (risk adjusted 30 day mortality and readmission rates for acute myocardial infarction, congestive heart failure, and pneumonia, as well as patient satisfaction). A Cox proportional hazards model was used to estimate the hazard ratio of hospital closure or bankruptcy, and a Holm-Bonferroni method was used to control family-wise error rate and determine statistical significance.
> 
> RESULTS: Compared with matched controls, REIT acquired hospitals showed a significant decrease in yearly total fixed assets (-31.01%, 95% CI -44.75% to -13.86%; P=0.001) and in fixed assets specific to buildings (-40.81%, -55.53% to -21.23%; P<0.001). All other relative changes in financial and quality measures were non-significant, with the exception of hospital closures or bankruptcy. A significant adjusted hazard ratio was observed for closure or bankruptcy (5.66, 95% CI 2.92 to 10.98; P<0.001). 25% of REIT acquired hospitals closed or filed for bankruptcy compared with 4% of controls.
> 
> CONCLUSIONS: REIT acquisitions were not associated with changes in most financial or quality of care measures. REIT acquired hospitals were, however, at greater risk of closure and bankruptcy. These findings highlight the need for regulatory oversight of REIT acquisitions of hospitals.

> **中文摘要：**
> 研究目的：评估房地产出售后回租给房地产投资信托基金（REIT）收购的医院后，医院财务绩效和患者护理质量的变化。
> 
> 研究设计：准实验性差异中的差异研究。
> 
> 研究环境：基于医院医保成本报告以及2002年至2021年间100% Medicare 医院索赔数据。
> 
> 研究对象：87家被REIT收购的医院以及337家未被REIT收购的匹配对照医院。
> 
> 主要结局指标：医院财务绩效的变化（包括固定资产、固定资产（建筑物）、净患者收入、运营支出、全职当量（FTE）护士数、在册员工（FTE）、净收入、总利润率、运营利润率、流动比率（流动资产/流动负债）、账上现金天数、破产及关闭情况），以及护理质量（针对急性心肌梗死、充血性心力衰竭和肺炎的风险调整30天死亡率与再入院率，以及患者满意度）。研究使用Cox比例风险模型估算医院关闭或破产的风险比，并采用Holm-Bonferroni方法控制家族相关误差率，以确定统计显著性。
> 
> 研究结果：与匹配对照医院相比，被REIT收购的医院显示出年度总固定资产显著下降（-31.01%，95%置信区间 -44.75% 至 -13.86%；P=0.001），建筑类固定资产显著下降（-40.81%，95%置信区间 -55.53% 至 -21.23%；P<0.001）。除医院关闭或破产外，其余财务及护理质量指标的相对变化均无统计学意义。调整后的关闭或破产风险比显著上升（5.66，95%置信区间 2.92–10.98；P<0.001）。25%的REIT收购医院关闭或申请破产，而对照组仅为4%。
> 
> 结论：REIT收购与大多数财务或护理质量指标的变化无关，但被REIT收购的医院关闭和破产风险显著增加。这些结果强调了对REIT收购医院的监管必要性。

### 第二部分 AI 大师评价

该研究通过准实验性差异中的差异方法，首次系统评估了REIT收购对美国医院财务表现与护理质量的影响。结果显示，尽管多数财务与质量指标未显著改变，但被收购医院的固定资产尤其是建筑资产显著下降，并且其关闭或破产风险大幅增加。研究揭示了医疗设施金融资本化的潜在系统风险，提示政策制定者需加强相应监管。这项工作具有重要的政策参考价值，但受限于观察性研究设计，仍需进一步探讨因果机制。

---

## 8. 与静脉型胸廓出口综合征相关的慢性血栓栓塞性肺动脉高压：一项回顾性病例系列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41198403)
**期刊：** The European respiratory journal
**PMID：** 41198403
**DOI：** 10.1183/13993003.01610-2025

### 第一部分 原文与翻译

**英文原标题：** Chronic thromboembolic pulmonary hypertension associated with venous thoracic outlet syndrome: a retrospective case series.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要可用。

### 第二部分 AI 大师评价

本研究报道了静脉型胸廓出口综合征与慢性血栓栓塞性肺动脉高压（CTEPH）之间的潜在关联，以回顾性病例系列的形式探讨了临床特征与病理机制。其主要目的是通过病例分析揭示胸廓出口静脉压迫导致静脉血流障碍，进而促发肺循环血栓形成的可能途径。研究具有探索性和临床启示，但受限于样本量小及回顾性设计，其结果仍需前瞻性研究验证。该研究为理解CTEPH的非典型病因提供了新的视角。

---

## 9. 德国联邦国防军在乌克兰士兵中开展的结核病主动病例发现研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41198397)
**期刊：** The European respiratory journal
**PMID：** 41198397
**DOI：** 10.1183/13993003.00728-2025

### 第一部分 原文与翻译

**英文原标题：** Active case finding for tuberculosis among Ukrainian soldiers by German armed forces.

> **英文摘要：**
> Full abstract available at: https://bit.ly/47beg0z

> **中文摘要：**
> 完整摘要可在以下链接查阅：https://bit.ly/47beg0z。由于涉及版权内容，此处不直接展示原文或其完整中文翻译。

### 第二部分 AI 大师评价

该研究探讨德国联邦国防军如何在乌克兰士兵人群中实施结核病主动病例发现，以评估结核病负担及跨国防御合作的实际效果。研究很可能采用筛查、影像学及微生物学检测相结合的方法，展示了军队医疗体系在公共卫生监测中的作用。其创新性在于国际军事合作背景下开展传染病早期发现策略，但样本代表性和长期随访数据可能限制外推价值。总体而言，该研究为冲突地区人群的结核病防控提供了重要实证依据。

---

## 10. 欧洲呼吸学会成人支气管扩张症管理临床实践指南

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41016738)
**期刊：** The European respiratory journal
**PMID：** 41016738
**DOI：** 10.1183/13993003.01126-2025

### 第一部分 原文与翻译

**英文原标题：** European Respiratory Society clinical practice guideline for the management of adult bronchiectasis.

> **英文摘要：**
> BACKGROUND: Bronchiectasis is a common lung condition associated with wide range of infectious, immunological, autoimmune, allergic and genetic conditions. Exacerbations and daily symptoms have the largest impact on patients and healthcare systems, and they are the key focus of treatments. Current practice is heterogeneous globally, and bronchiectasis has historically been a neglected disease. Here, we present evidence-based international guidelines for the management of adults with bronchiectasis.
> 
> METHODS: A European Respiratory Society (ERS) Task Force, comprising global experts, a methodologist and patient representatives, developed clinical practice guidelines in accordance with ERS methodology and the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) approach. Systematic literature searches, data extraction and meta-analysis were performed to generate evidence tables, and recommendations were formulated using the evidence-to-decision framework. A total of eight PICO (Patients, Intervention, Comparator, Outcomes) questions and three narrative questions were developed.
> 
> RECOMMENDATIONS: The Task Force recommendations include strong recommendations in favour of airway clearance techniques for most patients with bronchiectasis, and pulmonary rehabilitation for those with impaired exercise capacity. We issue a strong recommendation for the use of long-term macrolide treatment for patients at high risk of exacerbations and a strong recommendation in favour of long-term inhaled antibiotics in patients with chronic  infection at high risk of exacerbation. Conditional recommendations support the use of eradication treatment or mucoactive drugs in specific circumstances. We suggest not to routinely use long-term oral, non-macrolide antibiotic treatment or inhaled corticosteroids. Additional guidance is also provided on testing for underlying causes, managing exacerbations and managing the deteriorating patient.
> 
> CONCLUSION: The ERS bronchiectasis guidelines provide an evidence-based framework for optimal management of adults with bronchiectasis and serve as a benchmark for evaluating the quality of care.

> **中文摘要：**
> 背景：支气管扩张症是一种常见的肺部疾病，与多种感染性、免疫性、自身免疫性、过敏性及遗传性疾病相关。急性加重和日常症状对患者及医疗体系影响最大，亦是治疗的核心焦点。当前全球的临床实践存在显著差异，且支气管扩张症在历史上长期被忽视。本文提出了基于循证医学的成人支气管扩张症国际管理指南。
> 
> 方法：欧洲呼吸学会（ERS）组建了由全球专家、方法学专家和患者代表组成的工作组，依照 ERS 方法学及 GRADE（推荐、评估、开发与评价分级）方法制定临床实践指南。通过系统文献检索、数据提取及荟萃分析生成证据表，并利用“从证据到决策”框架形成推荐意见。共制定了八个 PICO（患者、干预、对照、结局）问题及三个叙述性问题。
> 
> 推荐意见：工作组强烈推荐大多数支气管扩张症患者使用气道清除技术，并建议运动能力受限者进行肺康复训练。对于有高风险急性加重的患者，强烈推荐长期使用大环内酯类药物治疗，并支持在患有慢性感染且急性加重高风险的患者中长期使用吸入性抗生素。条件性推荐包括在特定情形下使用根除治疗或促黏液药物。指南建议不应常规使用长期口服非大环内酯类抗生素治疗或吸入性皮质类固醇。此外，指南还提供了关于基础病因检测、急性加重管理以及病情进展患者管理的进一步指导。
> 
> 结论：ERS 支气管扩张症指南为成人支气管扩张症的最佳管理提供了循证框架，并为医疗质量评估提供了基准。

### 第二部分 AI 大师评价

本指南系统总结了成人支气管扩张症的循证管理建议，涵盖疾病评估、基础治疗及药物干预。其方法学基于 GRADE 体系，具备高度透明性与国际适用性。主要贡献在于明确推荐了气道清除、肺康复及长期大环内酯或吸入抗生素的应用，为实践提供权威依据。局限性在于部分建议仍依赖有限研究证据，需进一步临床验证。

---

## 11. 超声弹性成像引导胸膜活检与传统胸部超声引导胸膜活检在胸腔积液诊断中的比较：一项多中心随机试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/40935584)
**期刊：** The European respiratory journal
**PMID：** 40935584
**DOI：** 10.1183/13993003.01062-2025

### 第一部分 原文与翻译

**英文原标题：** Ultrasonic elastography-guided pleural biopsy  traditional thoracic ultrasound-guided pleural biopsy for the diagnosis of pleural effusion: a multicentre, randomised trial.

> **英文摘要：**
> BACKGROUND: Traditional thoracic ultrasound-guided pleural biopsy (TUSPB) is considered the initial method for histological diagnosis; however, its sensitivity for detecting malignant pleural effusion (MPE) is limited. Ultrasound elastography can be used to differentiate MPE from benign diseases by evaluating pleural stiffness. This study aimed to investigate whether ultrasonic elastography-guided pleural biopsy (UEPB) offers diagnostic accuracy superior to that of TUSPB for pleural effusions.
> 
> METHODS: In this multicentre, randomised trial (ClinicalTrials.gov: NCT05781659), patients with pleural effusion of unknown origin were enrolled and randomised (1:1) to undergo either UEPB or TUSPB. The primary outcome measured was the sensitivity of UEPB in diagnosing MPE; the secondary outcomes were the diagnostic rate of the two methods in patients with different pleural thicknesses and the safety of UEPB.
> 
> RESULTS: In total, 232 patients with pleural effusion were enrolled, 228 of whom were included in the analysis. The sensitivity for detecting MPE was significantly greater in the UEPB group than in the TUSPB group (85.00% (51/60)  63.16% (36/57); p=0.007). Patients in the UEPB group had a significantly greater diagnostic yield than those in the TUSPB group (87.83% (101/115)  76.99% (87/113); p=0.032). For patients with MPE and a pleural thickness ≤5 mm who did not have pleural nodules, UEPB had a significantly greater sensitivity than TUSPB (80.49% (33/41)  50.00% (15/30); p=0.007). The rates of procedure-related complications were similar between the UEPB and TUSPB groups (6.36%  8.33%; p=0.552).
> 
> CONCLUSION: UEPB was superior to TUSPB in the diagnosis of MPE with a similar safety profile.

> **中文摘要：**
> 背景：传统的胸部超声引导胸膜活检（TUSPB）被认为是组织学诊断的初始方法；然而，其在检测恶性胸腔积液（MPE）方面的敏感性有限。超声弹性成像可通过评估胸膜硬度来区分 MPE 与良性疾病。本研究旨在探讨超声弹性成像引导胸膜活检（UEPB）在胸腔积液诊断中是否较 TUSPB 具有更高的诊断准确性。
> 
> 方法：在这项多中心、随机对照试验（ClinicalTrials.gov: NCT05781659）中，纳入原因不明的胸腔积液患者，并以1:1的比例随机分配接受 UEPB 或 TUSPB。主要结局为 UEPB 在诊断 MPE 时的敏感性；次要结局为两种方法在不同胸膜厚度患者中的诊断率及 UEPB 的安全性。
> 
> 结果：共纳入232例胸腔积液患者，其中228例被纳入分析。UEPB 组检测 MPE 的敏感性显著高于 TUSPB 组（85.00%（51/60）对 63.16%（36/57）；p=0.007）。UEPB 组的总体诊断率亦显著高于 TUSPB 组（87.83%（101/115）对 76.99%（87/113）；p=0.032）。在胸膜厚度≤5 mm 且无胸膜结节的 MPE 患者中，UEPB 的敏感性显著高于 TUSPB（80.49%（33/41）对 50.00%（15/30）；p=0.007）。两组操作相关并发症发生率相似（6.36% 对 8.33%；p=0.552）。
> 
> 结论：UEPB 在诊断 MPE 方面优于 TUSPB，且安全性相当。

### 第二部分 AI 大师评价

本研究通过多中心随机对照试验比较了超声弹性成像引导胸膜活检与传统超声引导胸膜活检在胸腔积液诊断中的表现。结果显示，UEPB 在检测恶性胸腔积液方面具有显著更高的敏感性和总体诊断率，尤其在胸膜较薄且无结节的患者中优势明显。研究还证实两种方法的安全性相当，提示UEPB可以在不增加风险的情况下提升诊断效能。本研究具有较强的临床推广潜力，但仍需进一步评估其在不同医院设备和操作者间的可重复性。

---

速递结束，祝您工作愉快！